Clinical strategy
See the regimen, the comparator, endpoint deltas, safety profile, NCT, and source in one evidence trail.
Oncology intelligence for decisions that need to hold up
From oncology signal to a decision you can defend.
Pythia connects clinical evidence, patient segmentation, competitive context, and value. Explore what is changing, whom it matters for, and what it means for your asset.
Trial-level evidence, not a black-box summary
Comparator-aware efficacy and safety context
Patient segments that stay connected to the science
Every decision input traces back to a source
SoC Engine
ColorectalTODAY'S SOC CLINICAL RESULTS
1L metastatic CRC, RAS wild-type
Source-linked
mOS
38.7 mo
Treatment
mPFS
13.1 mo
Treatment
ORR
72%
Treatment
Doublet + EGFR antibody
Phase 3 · 1L metastatic · RAS wild-type
Median OS+9.7 mo
Median PFS+2.7 mo
NCT source and comparator arm availableView evidence
FUTURE SOC SIGNAL
HER2-directed ADC combination
Target, population, efficacy, safety, and source connected
One connected system
The intelligence stack behind an oncology decision.
Pythia follows the way strategy teams actually work: start with the science, define the population, understand the benchmark, then size the opportunity.
Portfolio intelligence
Interrogate a therapeutic area by biomarker, modality, molecule, sponsor, and line of therapy.
Asset strategy
Set a defensible TPP benchmark against the standard a product will actually have to beat.
Business development
Carry a sourced clinical thesis through patient sizing, rNPV, sensitivities, and deal economics.
A different angle on the landscape
A map is only useful when it changes the next move.
Pythia does not stop at showing who is active. It makes the clinical and commercial implications inspectable for every relevant population.
01
Find the signal
Map the target, modality, sponsor, trial, and patient population before the narrative gets noisy.
02
Put it in context
Compare emerging data with the current and future standard of care in the same line of therapy and biomarker-defined population.
03
Make the decision
Turn clinical differentiation into an addressable segment, a target product profile, and a transparent valuation case.
Evidence that stays auditable
The answer is only as useful as the evidence behind it.
Pythia keeps the source, trial, arm, population, and endpoint close to every analytical output. When the numbers change, you can see why.